Products
Products

HNSP has a broad range of products including:
  • 13 peptides at different stages of development:
  • four peptide intermediates shipped to U.S. clients
  • 23 small-molecule drug products in 36 strengths:
  • Approved, filed, or to be filed by NMPA, U.S. FDA or EMA
  • Leading HNSP products currently include:
U.S. FDA Approval
Treatment of moderate to severe dementia of the Alzheimer’s type
Thymalfasin for Injection, 1.6mg
NMPA/EMA (Italy) Approval

Chronic Hepititis B, immune response enhancer
Influenza vaccination in immunocompromised individual
Bivalirudin for Injection, 250 mg
NMPA/U.S. FDA Approval

Percutaneous Coronary Intervention (PCI)
Percutaneous Trans Luminal Coronary Angioplasty (PTCA)
Pregabalin Capsule, 75 mg, 300 mg
U.S. FDA Approval

Neuropathic pain associated with DPN; PHN, etc.
Eptifibatide Injection, 20mg/10mL
ANDA/NMPA Review

Treatment of acute coronary syndrome   (ACS) managed medically or with percutaneous coronary intervention

Product display
  • Levocarnitine for Injection
    Levocarnitine for Injection
  • Clindamycin Hydrochloride for Injection
    Clindamycin Hydrochloride for Injection
  • Inosine for Injection
    Inosine for Injection
  • Famotidin for Injection
    Famotidin for Injection
  • Sodium Ferulate for Injection
    Sodium Ferulate for Injection
  • Scopolamine Butylbromide for Injection
    Scopolamine Butylbromide for Injection
  • Ligustrazine Phosphate for Injection
    Ligustrazine Phosphate for Injection